Strengthening brain

"Strengthening brain" is not a recognized molecular target, such as a protein, receptor, or enzyme, within standardized pharmacological or genomic databases like UniProt or the IUPHAR/BPS Guide to PHARMACOLOGY. Instead, it serves as a functional descriptor or a therapeutic objective associated with cognitive enhancement, neuroprotection, and the promotion of synaptic plasticity. In drug discovery, such outcomes are typically achieved by modulating specific molecular entities, most notably Brain-derived neurotrophic factor (BDNF) and its receptor, Tropomyosin receptor kinase B (TrkB) (Source: NIH, "The Role of BDNF in Learning and Memory"). Because the term describes a physiological result rather than a discrete biological structure with a defined sequence, it cannot be categorized under specific molecular families or assigned direct drug interactions. Consequently, "Strengthening brain" is classified as an incorrect target name for the purposes of structured data entry and target-based drug development. Future research or analysis should instead focus on specific biomarkers or pathways like the glutamatergic system or neurotrophic signaling that contribute to improved brain function (Source: PubMed, PMID: 29445105).